Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-10
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
All right. Good morning, and thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I am Devjit, one of the therapeutic analysts, and it's my privilege to welcome our next presenting company, Precision. And joining from Precision are CEO Michael Amoroso and, obviously, Chief Scientific Officer Cassie Gorsuch. Thank you both for making time for us. You guys are on our roll right now. Let's start with the most recent data update that happened just over the weekend. Take us through the HPV landscape as to how you see it evolve.
Sure. So first of all, good morning, everybody, and Debjit, good to see you. We are on a roll because of science, real sound science for people like Cassie. This was her baby, so I'm going to let her talk to you about what we just presented at the late-breaking oral presentation this last weekend in Denver at AASLD. Cassie?
Sure. Yeah, it's really, thank you all for being here, and thank Thank you for the question, Debjit. So at Precision, we're a gene editing company. That's the central thesis behind all of our programs. Our hepatitis B program is now moving to a phase two study. So that was really the excitement to see that this program continues to advance. What we showed was that a first in class, really the only of its kind gene editing approach that is aimed at eliminating CCC DNA in the liver now has demonstrated a very robust data package with consistent loss of our biomarker, pgRNA, really important biomarker that I'm sure we'll get into, as well as biopsy evidence of proof of mechanism of eliminating CCC DNA in the liver, leading to durable and sustained consistent pgRNA loss across now a more robust data set. We've selected our go-forward dose for our Phase II study of 0.4 milligrams per kilogram on the basis of both safety and efficacy. So that was really an exciting opportunity to share the data with the field and show the progression of the program.
Got it. So let's unpack that a little bit on the pgRNA side and on the, you know, the reservoir, given the 1 to 1.5 log decrease in ccc DNA. There seems to be still a reservoir left, but the pgRNA is undetectable. Can you sort of help us understand that? Great question.
Yeah, happy to. So, pgRNA has a blood biomarker. We know it's a good biomarker. It's been published to be associated with, if you have undetectable pgRNA, better chances of sustained off-therapy cure. And so, we know it is a valuable biomarker, and we like it for our specific mechanism because pgRNA only comes from cccDNA. So PB gene, HPV, is designed to eliminate the viral reservoir in the liver, CCC DNA, and that's the source of pgRNA. The other upside of pgRNA, the reason it's a great biomarker, is that pgRNA is the source of HPV DNA. HPV DNA is the circulating infectious particles that lead to transmission between people, and importantly, it's the regulatory endpoint. So undetectable HBV DNA off treatment for at least six months is required by FDA in finite course treatment approaches for hep B like ours is. And so pgRNA sits in this really important middle spot between CCC DNA and HBV DNA, and it's detectable while patients are on nukes. And so it's our biomarker that we follow. Now, CCC DNA in the liver, to your question about the biopsies, what we're measuring in our biopsies is actually beyond the DNA level. We're looking at RNA transcripts in the biopsies. The reason we chose to do that is it allows a deeper, more sensitive analysis of what's going on in the liver. DNA, CCC DNA is very hard to detect in e-antigen negative patients who've been nuke suppressed for many years. Looking at the transcript level actually allows you to look deeper, see more than you can at the DNA level. So we're looking at transcripts. What we see in our two biopsies is proof of principle, proof that PBG and HPV gets to the liver and eliminate CCC DNA, driving, as you said, a tenfold or one log and one and a half log respectively in our two biopsy patients decreases in CCC DNA-derived transcripts. So we know even in the absence of pgRNA blood biomarker that you can see CCC DNA transcripts in the liver and you can see further reduction. So what does that mean if we bring it up a level? What it means is that there is value in treating patients who are pgRNA undetectable because you can see cccDNA reduction in the liver. You can still see cccDNA elimination beyond what you can see in the blood. However, we know that the blood biomarker correlates with improved odds of stopping nukes. So what we take all of that to mean is that in the phase two study, our goal is to provide a finite course of treatment for patients, Three administrations, 0.4 mg per kg on a Q8-week schedule. Even if the blood biomarker is undetectable, we know that there's still benefit of driving deeper CCC DNA reductions in the liver, and that's the plan for the Phase II study. We know that that biomarker correlates with improved odds of stopping nukes.
I'll just make one small point there. If you look at our data on the swimmer's plot, the very important data where we talked about if you go green, that's a good thing, and we stay undetectable after you've been dosed with PBG and HPV. To Cassie's point, the go-forward dose will be 0.4 mg per kg, eight weeks apart, three times. We didn't have any patient that needed more than two doses, Debjit, to go undetectable, but we know the liver could still be even more sensitive to tissue and have some small amounts of ccDNA, so we make that third administration to make sure we give the patient best chance of cure once you stop all therapies.
Another point of contention and debate really is the difference between a viral cure and a functional cure. Could you walk us through where you land up on that? What's more important here?
I'm going to have you take us through the cast. I'm just going to make one point. Debjit, what he just said, is profound. The fact that one AAASLD ago, we only talked about one pathway that existed through the FDA, functional cure, which is better than nothing, and it's a suppression endpoint. But HCC rates are still on the rise. You want to extinguish this virus permanently off therapies. Cassie, with that, now that we have some tools to focus on that, I think it's great that we're talking about both pathways that exist already in the FDA guidance. Cassie?
Sure. So I think maybe to start, just to elaborate on what Michael just said, there are two paths through FDA. Both of them require HPV DNA undetectable for at least six months off all therapies. And then functional cure layers in as synogen. I think what's important here is if we can take a step back and think about what's the goal, what should be the goal in hepatitis B treatment. And if you go back in the literature beyond when we became, you know, this idea of suppressing S, if you go before that, the field has always agreed that CCC DNA elimination is really the ideal therapeutic strategy. That's in the published literature, many, many different places. It's also widely accepted that if you eliminate CCC DNA, you'll cure hepatitis B. The challenge is we never had a tool, a clinical modality that could actually do that. And so we took different approaches to try to control the infection, to try to suppress viral proteins like astanogen with the goal of achieving immune control of the viral infection. But the goal for a viral infection should really be to cure the viral infection. And the way to do that is CCC DNA elimination. And so that's what we are aimed at doing is eliminating CCC DNA, providing a viral cure to patients. No chance of viral relapse in the future because CCC DNA and their viral infection is gone.
How do you think S-antigen is going to evolve over time? Do you expect it to plateau? Do you expect it to continue dropping?
Yeah, so with our mechanism, maybe I'll take a step back, not our mechanism, just basic virology-biology for a second. S-antigen comes from both CCC DNA and integrated DNA. Now, CCC DNA makes new infectious particles. Integrated DNA does not. And so the S antigen that comes from the two is asymmetrically more important to get the CCC DNA and get the S antigen that's coming from CCC DNA. So when you think about our mechanism of eliminating CCC DNA, you do expect some amount of S reduction. Now, every patient, the ratio of the S that comes from CCC DNA versus integrated DNA, that's going to be different in every individual. So there's not It's not a set threshold by which you would expect to see S come down. It depends on how much S is coming from CCC DNA in that patient. But you would expect to see reductions, and it should be stable over time after treatment with PB gene. And that is what we see. We see a 40% to 60% reduction in S antigen that is stable in all of our patients. Now, over many, many years, will that S-intogen continue to decline because of hepatocyte turnover and loss of integrated DNA? Maybe. I think we will need to see how that bears out in the data. There is evidence that integrins decrease over time.
Deb, did I just add one thing to your question of where do we see it going? I think S is an absolute, it's an indiscriminate, it's a nonspecific blood biomarker. All patients have it, and it's important to track longitudinally with treatment. I think... That never goes away. I think how we've thought about S now gets actually deeper. You've got to think about what source it's coming from. We've never been able to delineate that until now. And I am saying the S that comes from CCC DNA, the only replication-competent source in the body for more virus, is asymmetrically more important. So all viral transcripts and all viral proteins coming from CCC DNA. Have to be gone. You must eliminate to get the cure. I think S will be always observed. It being the end-all be, I think what ceases to exist going forward on new modalities, I don't think we're going to look to get S to undetectable and expect the body to turn on and get rid of the virus, because we've done a great job in 50 years at that, but we've done nothing about curing the virus. So I think you'll track S as a valuable treatment biomarker, but I think having therapies that target S only and praying for immunology, I think that ends. I think you'll start to see more people. Targeting at the DNA level the actual virus reservoir versus the RNA or the downstream protein level. I think that's what will change going forward.
Yeah, I mean, I think the problem, as people try and understand this better, everybody has been thought to think about. S-antigen. Yes. And now you're introducing a different paradigm here, which takes time to evolve or may be understood properly. There was one patient who had positive S-antigen. What do we make of that? Or was that patient unique?
Oh, I think you may be talking about first E antigen. Yes. Okay. So E antigen is a marker. It's a viral protein that gets made and it's present in early infected patients. So in the natural course of hepatitis B individuals, when people are first infected, they're all E antigen positive. And then over time shift to E antigen negative. What we know about those E positives is that they have two to three logs, higher CCC DNA levels in their liver. They have more infected hepatocytes, and they have more pgRNA in the blood. You can see in our data that our first antigen-positive patient had nearly 6,000 copies of pgRNA in the blood compared to, at most, a couple hundred in the e-antigen-negative patients. So this is an important population because they're difficult to treat because of the high burden of cccDNA, the high viral burden, and they have this higher cccDNA reservoir in their liver. And so we were really thrilled that when we moved into this population, the first patient that we dosed at 0.4 mg per kg demonstrated a complete loss of detectable pgRNA in the blood. And that tells you, that's at our go-forward dose of 0.4, by the way. And what that tells you is that that dose level is sufficient to achieve the biodistribution across the liver to get to all those infected hepatocytes in an E-positive patient where the task is harder, and it is sufficient to drive potent CCC DNA elimination even under higher viral burden situation. And so I think that that data, super exciting data, I think it's been hugely impactful for all of the KOLs that we've talked with, our investigators, and ourselves, that the 0.4 mg per kg is the right dose for our phase two study.
Yeah, this is the first time I think you can You can see a, regardless of viral burden, Because we're not focusing on masking or suppressing downstream, we're going at the source of the virus, at the DNA level, you're seeing, regardless of amount of virus, a ubiquitous treatment effect. That's profound, because we leave no patient behind.
Hypertension was an issue previously. Looks like you guys have mitigated that. Is that the approach that's getting carried forward?
Absolutely correct. Yeah, we learned a lot in our phase one. I mean, phase one by design is dose escalating and finding. So this is really the first therapy. Because you're using cumulative editing to cut out the CCC DNA, the virus at the liver, you do need those three administrations. Subsequent administrations of an LNP can absolutely cause an inflammatory or cytokine response. We've learned a lot about that and how to mitigate that. Cassie, why don't you talk the group through that?
Sure. So one of the things that we learned in the phase one experience was that on repeat administrations, we saw an inflammatory response associated with the lipid. And we put in place some pretty practical, simple mitigations to help prevent that inflammatory response. So we extended the duration of the infusion from two hours to five hours. We also increased the amount of steroids that our participants were getting on the day of dosing. So they already were pre-prescribed steroids the day before and the day of. On that day of, we took it from 10 milligrams to 20 milligrams of dexamethasone. And then we also prophylactically provided a saline infusion with the drug infusion. And so those pretty easy-to-implement medications have continued to be effective, as you mentioned, for hypotension at that 0.4 mg per kg dose level. So we do not see hypotension at 0.4 with subsequent or first doses across any of the patients dosed under that current infusion protocol, and we will absolutely be taking that with us to our Phase II study.
The only other thing I'd add, and Cassie might have said it is. When we first started, we had a full dosing regimen of two hours. We learned, as we've seen in all LMP programs, that first hour and the rate at what you infuse is super important. We have a totality of about a five-hour infusion. So we slow down the rate, simply take the steroids from 10 to 20 on the day of, push the saline prior to first administration and subsequent administrations, and we have not reproduced those hypotensive results. So we feel really good, Debjit, about the 0.4 mg per kg going forward that we really understand.
So another question on the tolerability side, the delayed increase in ALT that you're observing. We had the one, yeah. Is that... A viral clearance, or is that cumulative talks of the LNP?
Billion-dollar question. I think we feel really good with the LNP experts of the world that it's absolutely outside of the LNP window. We've seen it with other drugs. I'll let Cassie talk about the time frame of maybe an LNP, ALT, AST flare versus maybe an antiviral. I will say this. At all dose levels, even double what we're going to be going forward with, we've never seen bilirubin on any administration beyond the upper limit of normal. That's super important. We've had no concerns about liver function or any synthetic liver failures. You have some transaminitis that can be associated with LNP and or... A viral antiviral effect. So Cassie, can you talk about what we saw in the one patient?
Yeah. So I think in the context of lipid nanoparticle programs like ours, there's really two different flavors of transaminase elevations. One happens right after the LMP infusion and is very likely related to the lipid itself interacting with hepatocyte membranes. And so that would happen within the first week or two after the infusion. What we saw in one patient at our 0.4 go forward Dose level was a delayed transaminase elevation, so it was three weeks after the LMP was infused, and based on LMP kinetics, that's outside the window of exposure. These transaminase elevations, as you point out, are interesting because they occur in the context of many different hep B studies and are often associated with antiviral effect in the liver. We need to do more work to understand the etiology for this particular individual, but they're not unfamiliar you're in the context of hep B antiviral clinical studies.
This, of course, was transient. LTAST peaked around the 300 marks, and of course, the patient returned to normal with no interventions. But this could be a really important sign of antiviral activity, and we need to continue to track that and try to understand from different immune markers. We're looking at that. That'll be important as we go forward.
Yeah, I want to get to DMD. So one more question on the HPV side. Yes, sir. You disclose the phase two plans, monotherapy plus the antisense. Could you talk about the baselines of what you're trying to enroll, and what would be the ideal data set that you're hoping to get to? Because this is a large market. I don't know if precision by itself can commercialize something like this.
Yeah, I will start off, and I'll ask Cassie to comment on it, and then we'll move to our other child, who we love, which is our DMD program, our Function DMD program. First and foremost, the viral monotherapy, viral cure, as we've just talked about, eliminating CCDNA, undetectable HPV DNA, off therapies, all therapies, in the FDA guidance, number one, the gold standard. That is the gold of the monotherapy arm. We are the CCC DNA drug. We target it. We eliminate it. So you'll have three doses of PBG and HPV monotherapy at 0.4 mg per kg. You'll look at your pgRNA blood biomarker when present, and you will stop. You'll know when your intervention should be in the course of time, whether it be two months to six months. We'll stop the nuke, and we'll look at viral cure rate. I'll remind everybody, it's at 0% today. We've never been able to target the DNA level. Subsequently, we won't ignore the fact that a new step forward has been taken, and congratulations to our partners at GSK, more important to Pape for Patients, but 3% functional cure, suppression, not getting rid of virus, but suppression has been the gold standard of nucleoside analogs. Now it goes to 19% on the back of Bepi. And we know Bepi works best in patients with the lower viral load, and you can track S-antigen as that marker for lower viral load. That's where Bepi had the more robust results. So what we're doing is in the monotherapy on, viral cure only, PB gene three times. In the combo on, we will look at PB gene three times. And then Bepi will be dosed as per their new approved label. First and foremost, you'll look at viral cure. If that CCC DNA biopsy marker left anything behind, and by the way, that was an absolute percentage of 0.08%, but maybe somebody could reinfect. My guess is some immune systems will keep it at bay, some will get rid of it. Some, potentially, I'm sorry, may not keep it at bay. So if there's any pgRNA left over to make an HPV DNA, Bepi could be very complimentary at cleaning up what was left in that less than 1%. Additionally, how do we potentially make Bepi better? Well, Bepi's... Approvable endpoint is functional cure. We know they don't get rid of the virus. And we know immunology is a big part of their mechanism. What you see there is, again, they work best when the viral load was lower. At a minimum, PBG eradicates more than 99% of the virus. So if you think about the patients that got the stop nukes in the BEPI trial, it was only about 24% of patients and 19 held. That leaves 80% of patients behind. Many of the BEPI patients got the S low, but not enough Low enough to stop the nukes. We think you might allow BEPI to have a much lower hurdle by first treating with PBG. So again, monotherapy arm, you'll look at viral cure, HPV DNA undetectable, line one in the FDA guidance. In the combo arm, we'll look at that same line to see if any cleanup was needed for PBG, but we will also get the shot on goal to say, did we improve the functional cure rate of 19%, which, frankly, we think we can do that for patients, too, because we think we make BEPI, we put BEPI into their sweet spot when we lessen the viral burden. That is what the phase two will show. It's open label. You'll be able to see rolling results starting the second half of next year.
Go ahead. One last one on this one before we go to DMD. Mostly, today, the trials are in Rolex US, right? Now, with the phase two, what are the plans for US trial, and let's move to DMD?
Very similar. We go where the patients are. So, we'll start in Asia. We're able to get fast traction there. We have a team already accruing, and then we'll onboard Eastern Europe to start, and then the US. So, it'll be, you're going to probably see about an 80% Asian population to about a 20% targeted Caucasian population. Very similar to what you see in, for example, the B-Wall trials.
Got it. So now back to your second child here. Yes. The one which is really close to my heart. Yes. So this is not a gene augmentation program, right? And what you're trying to get to is somewhat like an exon skipper, but on a permanent basis. Truncated DNA, almost 80%, the size of DNA, but truncated dystrophin, almost 80%, the size of normal. First patient, clean safety as of now. When do we see the data from the biopsy stuff? And by year end, how many do you plan to enroll?
Sure. So, Cassie, maybe you can give a quick overview for the crowd of what the program is. Super important, to Debjit's point, taking back the body's native dystrophin. And second, you can really talk about three quarters of the next four really important inflection points for DMD.
Sure. So, yes, you're right. It sits between an XM skipper and a micro dystrophin, and we think we take the best of both and improve on the limitations of both. So PB gene DMD is a gene editing approach that is designed to excise a frequently mutated hotspot region of the dystrophin gene between exons 45 and 55. So unlike exon skippers, it can be broadly applicable, and it's a one-time treatment. So broadly applicable for the majority of patients. Many, many, many patients have mutations in this hotspot region, not the case for exon skippers, obviously, that are mutation-specific, single-exon-specific. On the microdystrophin side, very, very small protein that is produced, unknown function in humans. The protein that we make with our approach is near full length dystrophin and known function in humans because it occurs in a subset of Becker patients with a very mild overall phenotype. So we think it improves upon the existing treatment landscape in really meaningful and important ways. So that's the approach for PBG and DMD. As you mentioned, we dosed our first patient in August at Arkansas Children's Hospital. All safety signs look good there. We shared that news recently. In terms of what's coming next, so the first question is how many patients by the end of the year? So our goal is to enroll part one of the study. That's our initial safety cohort by the end of the year. So that's our three initial participants enrolled. We've got patient two already enrolled, and we're screening patient three right now. So we're on track to complete that goal of enrolling those first three patients by the end of the year. Now, this program is taking multiple biopsies from these kids, so baseline biopsies, three-month biopsy, and 12-month biopsy. What we saw preclinically was that dystrophin expression grew in DMD disease mice over time, which is why we're looking longitudinal in the clinical biopsies too. So first half of next year, we expect to be able to share initial biopsy data from those initial patients on the study. That's the three-month biopsy data. More importantly, the 12-month biopsy data, where we will look to correlate it with functional outcomes, will come second half of next year. So I'm really excited for this program to continue to advance. I don't know if you want to add anything.
I know we're at time here. I just want to remind everybody that we were able to go out and bring in the back of the exciting data, both sets of data, $125 million to add to our pre-existing cash position. That takes us through 29 and, more importantly, through the key late-stage clinical inflection points, a full Phase II global HPV trial known as Eliminate-B, as well as we've now fully raised to fund on our own Pivotal for DMD. So these late catalysts will have a data-rich year next year in the next 12 months, and that's both programs, HPV and DMD, and onward in 28 and 29 for our DMD Pivotal. So exciting inflection points to come.
Well, congrats on the progress, and looking forward to a productive 27. Thank you, sir. Great to see you. Appreciate it. Thank you so much, guys.
0:01 to 25:59 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
All right. Good morning, and thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I am Devjit, one of the therapeutic analysts, and it's my privilege to welcome our next presenting company, Precision. And joining from Precision are CEO Michael Amoroso and, obviously, Chief Scientific…
Michael Amoroso: Sure. So first of all, good morning, everybody, and Debjit, good to see you. We are on a roll because of science, real sound science for people like Cassie. This was her baby, so I'm going to let her talk to you about what we just presented at the…
Also speaking: Cassie Gorsuch